Superior survival benefits of triple combination immunotherapy compared to standard chemotherapy as second-line treatment for advanced biliary tract cancer: a retrospective analysis
The triple combination of immunotherapy offers superior survival benefits compared to standard chemotherapy as a second-line treatment for advanced BTC, warranting further investigation for potential clinical adoption.
Authors
- Zhuo Cheng
- Tianmei Zeng
- Weidong Shen (ORCID: https://orcid.org/0000-0002-1712-9324)
- Guang Yang (ORCID: https://orcid.org/0000-0003-2920-6523)
- Zhi-ping Lian
- Heming Xu
- Peipei Shang (ORCID: https://orcid.org/0000-0002-8666-9869)
- Weipeng Hong
- Xiaoqiang Cui (ORCID: https://orcid.org/0000-0002-5858-6257)
- Cheng Lou
- Wei Wei (ORCID: https://orcid.org/0000-0003-2714-3346)
- Zhen-Gang Yuan
Institutions
- Second Military Medical University (CN)
- Chinese National Human Genome Center at Shanghai (CN)
- Eastern Hepatobiliary Surgery Hospital (CN)
- Viva Biotech (China) (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-11-22
- DOI
- https://doi.org/10.3389/fonc.2024.1482909
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00